Sävendahl L, Cooke R, Tidblad A, et al. - From the entire dataset of all eight countries (Belgium, France, Germany, Italy, The Netherlands, Sweden, Switzerland, and the UK) of the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) consortium, researchers obtained data of young adult patients who underwent treatment with recombinant human growth hormone during childhood in order to determine the long-term overall and cause-specific mortality among them and to relate this to the underlying diagnosis. Per their knowledge, this cohort is the largest comprising of 24,232 patients treated with recombinant human growth hormone during childhood, with more than 400,000 patient-years of follow-up. Significantly increased all-cause mortality was noted in children born small for gestational age, when analysed for all countries, but this result was driven by the French subcohort. Increased mortality was noted in patients at moderate or high risk. All risk groups showed increased cause-specific mortality from diseases of the circulatory and haematological systems. These findings revealed correlation of underlying diagnosis with all-cause mortality. In patients with isolated growth hormone deficiency or idiopathic short stature, there was no correlation of recombinant human growth hormone treatment with elevated all-cause mortality.